Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
Education Center - SponsoredHow artificial intelligence can enhance diagnostic confidenceby • ZoetisIn the right context, AI yields the power to enhance clinical confidence and streamline decision-making – without replacing the human touch that defines the profession.
